Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) has received an average rating of “Hold” from the six brokerages that are currently covering the company. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $2.50.
MRNS has been the subject of several recent analyst reports. Stifel Nicolaus downgraded Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 13th. Royal Bank Of Canada downgraded Marinus Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $14.00 to $2.00 in a research report on Tuesday, June 14th. Oppenheimer Holdings Inc. downgraded Marinus Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 14th. Goldman Sachs Group Inc. downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 14th. Finally, Jefferies Group restated a “buy” rating and set a $2.50 price objective (down from $13.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 14th.
In other Marinus Pharmaceuticals news, major shareholder Vii Lp Canaan sold 270,750 shares of the stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $1.90, for a total value of $514,425.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.00% of the stock is owned by company insiders.
A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Franklin Resources Inc. increased its position in Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) by 14.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,182,185 shares of the biopharmaceutical company’s stock after buying an additional 279,900 shares during the period. Franklin Resources Inc. owned 15.22% of Marinus Pharmaceuticals worth $11,740,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 45.64% of the company’s stock.
Marinus Pharmaceuticals (NASDAQ:MRNS) traded down 3.60% during trading on Monday, hitting $2.14. The stock had a trading volume of 742,767 shares. Marinus Pharmaceuticals has a 52 week low of $1.19 and a 52 week high of $12.28. The company has a 50-day moving average of $1.62 and a 200 day moving average of $3.41. The company’s market cap is $41.75 million.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.08. On average, equities research analysts anticipate that Marinus Pharmaceuticals will post ($1.65) EPS for the current year.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.